Patient Research
Find a studySpecialtiesConditionsTreatmentsBy countryLearn
Sign in
Research.Patient.info

Localized Scleroderma research hub

1 indexed studies · 0 currently recruiting

  • authorisedTherapeutic exploratory (Phase II)

    A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

    This study looks at a new medicine called lebrikizumab for people with localised scleroderma. Researchers want to see if it's safe and helps improve skin symptoms. Half the people will get the new medicine, and half will get a dummy medicine, without knowing which one they have.

    Germany
Advertisement
Advertisement
Advertisement
Patient.info Research

Find clinical research studies and trials explained in plain English - powered by Patient.info.

About
  • About us
  • Advertise with us
  • Partnerships
  • Authors
  • Contact us
Research explained
  • What is a clinical trial?
  • Trial phases explained
  • Why volunteer?
  • Clinical research FAQ
  • All health-research articles
Legal
  • About our content
  • Report a correction
  • Accessibility statement
  • Cookie policy
  • Privacy policy
  • Terms of use
  • Editorial policy
Find a study

Search clinical research studies and trials by condition, location and eligibility.

Browse studies →Learn about trials →
Information only. Research.Patient.info surfaces public clinical-trial registry data and explains it in plain English. We are not affiliated with the MHRA, HRA, NHS, NIHR or any regulator. Inclusion of a study is not an endorsement and is not medical advice — always discuss with your own doctor before agreeing to take part. See about our content or report a correction.
© 2026 Navigate Health Ltd. All rights reserved.
Registered number: 16229589
Registered office: 128 City Road, London, United Kingdom, EC1V 2NX.
Patient is a UK registered trade mark.
Patient does not provide medical advice, diagnosis or treatment.